Technology works. Markets do not always adopt it.

The structural distance between what a technology can demonstrably do and what an institutional market, as currently organized, will adopt. This gap persists for technically superior products. It is not caused by poor technology or poor intent — it is caused by structural conditions on the buyer side that are largely invisible until they block conversion.

Problem Clarity: The target buyer does not yet articulate their operational problem in terms that connect to the technology's capability. Buyer-side condition, not a seller communication failure.

Value Translation: Technical performance characteristics are not expressed in the buyer's operational and financial language.

Proof: The technology lacks the specific type of evidence the buyer's procurement process requires to advance.

Trust: Insufficient confidence in the technology company as a reliable long-term partner — at the institutional level, not interpersonal.

Process: The buyer's procurement timing, documentation format, and approval structure are not yet aligned with the vendor's commercial approach.

The Five Structural Gaps Diagnostic is available as an interactive ten-question instrument. It identifies your primary open gap from a practitioner-calibrated question set.

TRL (Technology Readiness Level): A nine-point scale measuring technical development maturity from basic principles (TRL 1) to proven deployment in operational environment (TRL 9). Established institutional standard (NASA, European Commission).

CRI (Commercial Readiness Index): Measures whether the market can be found, accessed, convinced, and contracted. A product can reach TRL 9 while remaining at CRI 1 or 2 — with no defensible market position, no reference customers, and no functional sales architecture.

Commercial readiness work must begin at TRL 5 or earlier — not after technical validation is complete. Technical teams can reach TRL 9 while the company has no commercial process, no reference strategy, and no procurement intelligence.

Pilots designed to validate technical performance do not automatically produce the evidence, relationships, or documentation required by institutional procurement processes. The pilot demonstrates what the seller needs to demonstrate — not what the buyer needs to see to proceed.

The exit conditions of a pilot are rarely defined before the pilot begins. They are negotiated afterward — by which point the buyer's internal process has not been prepared for a procurement decision.

Define exit conditions before the pilot begins. What must be true — in writing, at what scale, verified by whom — for procurement to proceed? Design the pilot backward from those conditions, not forward from the technology's strengths.

1 — Internal laboratory data
2 — Controlled pilot results (vendor-operated)
3 — Independent third-party verification
4 — Reference installations in adjacent sectors
5 — Reference installations in the same segment
6 — Reference customers willing to advocate in the buyer's specific context

The correct question is not "do we have evidence?" but "do we have the right type of evidence for this buyer's procurement stage?" Excellent evidence at the wrong rung does not advance procurement.

Vendor risk: Revenue loss from a failed sale.

Buyer risk: Operational failure, regulatory non-compliance, reputational damage, career risk, and organizational liability from a technology that does not perform as required over its operational life.

This asymmetry explains why buyers apply standards of proof that appear disproportionate. It is a rational institutional response, not excessive caution.

An institutional buyer procuring infrastructure that must operate for ten to twenty years is also buying a service relationship, a support commitment, and an organizational guarantee. Technical performance is necessary but not sufficient.

Buyer category + problem being solved + evidence required to advance + procurement process to navigate + conditions under which the vendor can be trusted. A commercial hypothesis is falsifiable by market evidence. A value proposition is a positioning statement. They are not the same instrument.

A commercial hypothesis allows a company to test whether its commercial assumptions match market reality — and to identify which assumption is wrong when commercial traction is absent.

Founder-led selling: Commercial mode in which the technology creator drives sales through personal credibility, technical knowledge, and relationship network. Effective and necessary in early market stages.

Commercial system: Replaces personal selling with documented processes, structured territory coverage, defined sales stages, and repeatable qualification criteria.

Adding sales headcount without first building the system creates underperforming sales hires, not scale. The hire can only leverage a system that does not yet exist.

Segment selection, channel architecture, representative network governance, reference customer strategy, regulatory environment mapping, procurement timeline alignment, and resource allocation sequencing.

Architecture describes structure. A plan describes activities. Most market entry failures in institutional B2B markets are architecture failures, not execution failures. The activities were carried out correctly within the wrong structure.

Load-bearing: Investments that directly close a structural gap — producing a reference installation, developing a third-party verification protocol, building a compliance documentation system.

Decorative: Investments that generate visible commercial activity without advancing the structural conditions required for procurement — trade fair participation when the primary gap is institutional trust; a new brochure when the primary gap is missing reference installations.

The same investment can be load-bearing in one commercial context and decorative in another. The distinction is gap-specific. Without gap diagnosis, commercial budgets reliably optimize toward visible activity rather than structural progress.